Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT01938326 Completed - Clinical trials for Early Gastric Cancer

Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG)

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

1. Compare the immune response and postoperative complications between pure SIDG (single-incision laparoscopic distal gastrectomy) and TLDG (totally laparoscopic distal gastrectomy) for early gastric cancer (EGC) 2. Validate the safety, usefulness, minimal invasiveness and feasibility of SIDG (EGC)

NCT ID: NCT01938313 Completed - Gastric Cancer Clinical Trials

Early Recovery After Surgery (ERAS) Versus Conventional Protocol After Laparoscopic Gastrectomy

ERAS
Start date: August 2012
Phase: Phase 2
Study type: Interventional

Enhanced Recovery After Surgery (ERAS) programs have been introduced with purposes of reducing the surgical stress response and obtaining optimal recovery after surgery.

NCT ID: NCT01928524 Completed - Clinical trials for First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or

Chemotherapy for Patients With Cancer of the Stomach

DOS
Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.

NCT ID: NCT01928290 Completed - Stomach Neoplasms Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

FOLFIRINOX
Start date: November 8, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

NCT ID: NCT01926743 Completed - Gastric Cancer Clinical Trials

Identification of Complete Lymph Node Removal by Application of Near Infrared Fluorescence Imaging in Laparoscopic and Robotic Gastrectomy

Start date: August 1, 2013
Phase: N/A
Study type: Interventional

Lymph node dissection in gastric cancer surgery is a very important factor not only for exact acquisition of stage but also proper treatment. Realistically, it is impossible to identify complete removal of lymph node in dissected nodal station by naked eye. The investigators can assess the route of lymphatic drainage and identify residual lymph nodes in dissected area. In the field of gastric cancer treatment, ICG and near infra-red fluorescence imaging was used only detection of sentinel lymph nodes. However, this novel concept can help to understand lymphatic drainage and make surgeons to perform D1+ or D2 lymph node dissection completely.

NCT ID: NCT01924533 Completed - Gastric Cancer Clinical Trials

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Start date: September 3, 2013
Phase: Phase 3
Study type: Interventional

This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.

NCT ID: NCT01921673 Completed - Gastric Cancer Clinical Trials

Dovitinib Plus Docetaxel in Gastric Cancer

Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Docetaxel is currently one of standard second-line therapy in patients with gastric cancer. As angiogenesis and FGFR pathway has been suggested to be associated with gastric cancer, dovitinib, dual VEGFR and FGFR inhibitor, may have the potential to improve the outcomes of patients with gastric cancer. Therefore, we investigated the combination regimen of docetaxel and dovitinib.

NCT ID: NCT01914692 Completed - Clinical trials for Gastric Cancer After D2 Lymph Node Dissection

Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection

Start date: January 2013
Phase: Phase 4
Study type: Interventional

Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

NCT ID: NCT01910974 Completed - Stomach Neoplasm Clinical Trials

Multicentric Study an Endoscopic Treatment of Digestive Neoplasia by Submucosal Dissection Evaluation of a New Water Jet System

Start date: July 2012
Phase: N/A
Study type: Interventional

safety evaluation of endoscopic sub-mucosal dissection with nestis enki2 system. This system is a new water jet system which allows to perform Endoscopic submucosal dissection with a bifunctional catheter (injection and cutting).

NCT ID: NCT01904435 Completed - Gastric Cancer Clinical Trials

Cetuximab, Paclitaxel, Carboplatin And Radiation For Esophageal, Gastroesophageal Junction And Gastric Cancer

Start date: January 2005
Phase: Phase 2
Study type: Interventional

Phase II study of cetuximab, paclitaxel, carboplatin and radiation for esophageal cancer.